C14orf80 Inhibitors
Inhibitors of C14orf80 encompass an array of compounds that target specific biochemical pathways, ultimately leading to the reduction of C14orf80's functional activity. One class of inhibitors operates by mimicking the ATP binding site of protein kinases, which are responsible for the phosphorylation states regulating C14orf80. The presence of these inhibitors hinders the kinase's ability to phosphorylate C14orf80, thereby reducing its activity. Other inhibitors interfere with the PI3K/AKT pathway, where a blockage of PI3K prevents the activation of downstream AKT, a kinase which might be crucial for the functional activity of C14orf80. Inhibition of the MAPK/ERK and p38 MAPK pathways serves a similar end; by obstructing the signaling events mediated by these pathways, necessary phosphorylation events or regulatory mechanisms essential for C14orf80 activity are impaired. Additionally, certain inhibitors disrupt cell growth regulation by targeting mTOR, a pivotal controller of cell metabolism, which, when inhibited, could reduce the anabolic processes involving C14orf80.
Several inhibitors focus on the indirect regulation of C14orf80 by modulating the cell's internal environment. Inhibition of Calcineurin affects the dephosphorylation of transcription factors, which could be a requisite for C14orf80's function, such as in T-cell activation. By inhibiting Calcineurin, these compounds lead to a consequential decrease in C14orf80 activity. In a similar fashion, proteasome inhibitors impede the degradation of regulatory proteins that may control C14orf80's stability and function, causing an indirect decrease in activity due to the altered protein turnover. Additionally, compounds that inhibit HDAC can change the chromatin structure and gene expression patterns, which might be central to C14orf80's activity. Furthermore, the selective targeting of kinases involved in cell cycle progression, such as Aurora kinases, leads to cell cycle arrest, which could indirectly affect C14orf80's role in mitotic processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
This compound binds to FKBP12 and together they inhibit mTOR, a kinase downstream of C14orf80 signaling. Inhibition of mTOR leads to reduced protein synthesis and cell proliferation, which indirectly results in the decreased functional activity of C14orf80. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, this molecule prevents the phosphorylation and activation of AKT, interfering with the PI3K/AKT/mTOR pathway, which is crucial for cellular survival and growth signals that may involve C14orf80 indirectly. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
This compound specifically inhibits the activation of AKT, impeding downstream signaling that could affect C14orf80 function, especially if it is implicated in growth and survival pathways regulated by AKT. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
By selectively inhibiting p38 MAP kinase, SB203580 disrupts inflammatory cytokine production and cellular stress responses, pathways that may indirectly involve C14orf80. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
As a PI3K inhibitor, Wortmannin blocks the PI3K/AKT pathway, affecting downstream proteins such as C14orf80 that may be involved in cell growth and apoptosis. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
By inhibiting MEK, which activates ERK, PD98059 can suppress the MAPK/ERK pathway, thereby reducing the activity of proteins like C14orf80 that may be indirectly regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125 may alter the activity of transcription factors and apoptotic pathways that could indirectly decrease the activity of C14orf80 given it is associated with these cellular processes. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
This compound inhibits ROCK kinase, which plays a role in actin cytoskeleton organization. Disruption of this pathway can lead to changes in cell shape and motility that could impact C14orf80 activity assuming it's associated with these cellular structures. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets the EGFR tyrosine kinase and by doing so, it may indirectly affect downstream signaling pathways involving C14orf80, particularly if C14orf80 is associated with pathways regulated by EGFR signaling. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Another EGFR inhibitor, Erlotinib, could reduce the activity of downstream signaling pathways that may include C14orf80, especially if it is part of cellular proliferation processes governed by EGFR. | ||||||